Phase II/III (Integrated)

392 trials 186 recruiting

Filter these 392 trials by condition, country, sponsor and more.

Open in Search →

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With… Ended

2024-512163-31-00 Amyotrophic Lateral Sclerosis with Fused in Sarcoma mut 2022-01-26
A Study of Evorpacept (ALX148) in Patients with Advanced Gastric Cancer Ended

2023-509406-30-00 Patients with HER2-overexpressing advanced or metastati 2022-01-24
This study is a randomized, placebo-controlled, double-blind, multicenter Phase 2/3 study of patients, age 12 to 65 years, with sickle cell … Ended

2024-511535-97-00 sickle cell disease (SCD) 2021-12-16
Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus Ended

2024-513031-24-00 Moderate-to-severe Systemic Lupus Erythematosus (SLE) 2021-10-22
Atacicept in Subjects with IgA Nephropathy (ORIGIN and ORIGIN 3) Ended

2023-503772-24-00 IgA Nephropathy 2021-09-15
Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches Ended

2023-504447-14-00 Treatment of pediatric subjects with moderate to severe 2021-07-29
A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended

2022-502100-70-00 Participants with Microsatellite Instability-High (MSI- 2021-06-23
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended

2023-507132-21-00 Early Parkinson's disease 2021-05-11
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC… Ended

2023-507475-21-00 Lung Cancer, Non-Small Cell 2021-01-18
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80… Ended

2024-512232-30-00 Primary Biliary Cholangitis 2021-01-18
Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Diffuse Large B-Cell Lymphoma Ended

2024-513616-95-00 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR D 2020-12-22
A Clinical Trial to evaluate the Efficacy and Safety of of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patie… Ended

2024-517090-24-00 Recurrent or Metastatic HER2 Negative Breast Cancer 2020-10-09
Hepatic arterial infusion PUMP chemotherapy combined with systemIc chemoTherapy for potentially resectable colorectal liver metastases. - Th… Ended

2024-515525-28-00 colorectal adenocarcinoma 2020-09-10
Fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia A or B Ended

2024-512501-76-00 Hemophilia 2020-07-28
Extension of a clinical trial to assess the safety of a study drug called "CORT125134" in the treatment of Cushing Syndrome Ended

2024-514079-17-00 Endogenous Cushing Syndrome 2020-05-28
Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended

2023-509908-15-00 Mantle Cell Lymphoma 2020-01-20
Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) Ended

2022-502604-67-00 Malignant pleural mesothelioma (MPM) 2019-12-20
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504718-31-00 Moderately to Severely Active Ulcerative Colitis 2019-10-19
An efficacy and safety study of 2-OHOA in patients with glioblastoma Ended

2024-511542-39-00 Newly diagnosed primary glioblastoma multiforme (ndGBM) 2019-09-16
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Stu… Ended

2023-505321-14-00 Warm Autoimmune Hemolytic Anemia 2019-09-06
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Ended

2023-506777-36-00 Prostate Cancer 2019-01-04
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended

2024-513912-89-00 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofi 2018-12-13
DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended

2024-514945-12-00 locally advanced resectable adenocarcinoma of the oesop 2018-09-03
First-in-human study of AT132 in X-Linked Myotubular Myopathy (XLMTM) Patients Ended

2024-512637-32-00 X-linked Myotubular Myopathy (XLMTM) 2018-08-21